 |
Public Policy Holding Company reports first-half revenues grew 24 percent as it recorded robust demand for its government relations, PA and regulatory advisory services.
The acquisition of TrailRunner International (which was completed April 1), contributions from the 2024 deals for Pagefield Communications and Lucas Public Affairs, and 8 percent organic growth drove the firm’s financial performance.
Stewart Hall, CEO, said the strong results “reflect the ongoing trust our clients place in us and the value they derive from the PPHC platform.”
He sees great opportunities in the strategic communications sector as clients seek integrated support to manage complex reputational, regulatory and stakeholder challenge.
Earlier this month, PPHC announced the acquisition of Austin-based Pine Cove Capital in a deal valued at up to $13M.
Led by former Texas Land Commissioner George P. Bush and his wife, Amanda, Pine Cove will form the core of PPHC’s effort to build a Texas state government relations practice.
PPHC, which trades on the London Stock Exchange, also owns Seven Letter, Crossroad Strategies, Forbes Tate Partners, O’Neill & Assocs., Concordant, MultiState Assocs., Alpine Group Partners and KP Public Affairs.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
